


L.E.W.  CARTY  
CHARITABLE FUND



# 2023 ANNUAL REPORT

FOR YEAR ENDED 30 JUNE 2023

L.E.W. Carty Charitable Fund is a perpetual philanthropic trust established in 1977 under the Will of the late Olive Muriel Carty to honour the memory of her late husband Leslie Ernest William Carty, and commenced grantgiving in 1980.

It provides grants to selected charities within the State of Victoria to assist or promote research into the diagnosis prevention, or treatment of physical or mental disorders of humans. Grants to appropriate charities are determined at the absolute discretion of the Trustees.

## Trustees

Susan Harker (professionally known as Dr Susan Forrest), Chair  
Steven Lambeth  
Sally Wood

## Staff

Glen Thomson, Finance Executive  
Katie Costello, Program Manager (until January 2023)  
Nick Doherty, Grants Administrator

## Contact Us

Level 2, 90 Collins Street  
Melbourne Vic 3000

T: 03 9999 3090  
E: [info@carty.org.au](mailto:info@carty.org.au)  
W: [carty.org.au](http://carty.org.au)

ABN: 49 743 689 212

## Contents

|  |      |
|--|------|
| Chair's Report .....                   | 3    |
| Our Founder - Olive Muriel Carty ..... | 5    |
| Grants.....                            | 7    |
| Carty Signature Grant 2023.....        | 8    |
| Financial Summary.....                 | 9-10 |

*Cover image: Dr Kiryu Yap, recipient of the 2023 Carty Signature Grant*

# Chair's Report

I am pleased to present my Chair's Report of the L.E.W. Carty Charitable Fund for the year ended 30 June 2023.

In 2023, Trustees commissioned Born & Bred Historical Research to conduct historical research, oral history interviews and record analysis of the life of Olive. Findings of this research have been included in an updated summary of Olive's biography on page 5, with the full research to be published on our website.

## Grantgiving

Our Carty Signature Grants aim to help nurture mid-career researchers and, where practical, to retain leading researchers in Victoria. Grants can be awarded for basic research, clinical and public health and generally, one grant per year is awarded.

In FY23, the Trustees worked with St Vincents Institute of Medical Research to identify an outstanding candidate and were delighted to award the Carty Signature Grant to Dr Kiryu Yap, a post-doctoral Research Fellow. Kiryu is a clinician scientist and thus brings great insights to investigating treating non-alcoholic fatty liver disease using designer human liver organoids. You can read more about Kiryu's research on page 8 of this report.

## Investments

The objectives of the Fund's investment mission are twofold: firstly to achieve long-term appreciation of the value of the corpus, ahead of inflation, and secondly to generate sufficient income to fund the annual grant giving program and operating expenses. Long-term growth in the value of the corpus is essential if the Fund is to continue to serve Victoria's medical research community in the future as well as it has excelled in the past.

The Fund's overall investment objective is to achieve a total investment return of Consumer Price Index (CPI) + 5.0% over rolling 10-year periods. Of the total expected annual investment return, long term capital returns are targeted at CPI + 1.0% p.a. and income returns are targeted at 4.0% p.a. to cover granting and operating expenses.

Despite the challenge of a high inflationary environment and higher interest rates, the corpus performed strongly, generating a total return (including franking credits) of 16.8% for FY23, outperforming our long-term objective of 11.0% (CPI+5.0%) by 5.8%. The strong rebound in listed markets resulted in our Australian shares returning 17.2% and international shares returning 20.5%.

## Operating results

Revenue of \$580,578 was earned on the corpus during FY23, down 56% on the \$1,332,850 earned in

*continued ...*

## **Chair's Report** *continued*

FY22. This large decrease was due to the FY22 income being boosted by franked dividends received from participating in the Commonwealth Bank, Woolworths, and Westpac off-market share buy-backs.

Operating Expenses in FY23 (\$69,077) were materially in line with those incurred in FY22 (\$64,968).

After approving \$410,000 in grants for the FY23 year (FY22: \$300,000), there was a Surplus for the year of \$101,501 (FY22: \$967,882) of which \$90,151 remains in the corpus and \$11,350 will be used for grant making in future years.

## **Governance of the Fund**

The Fund is regulated by the Australian Charities and Not-for-profits Commission (ACNC) and is governed by a Board of Trustees which meets regularly throughout the year to consider the three core activities of the Fund: grantmaking, investment management, and finance / compliance.

## **Trustees and Management**

My thanks to my co-Trustees Sally Wood and Steve Lambeth whose commitment to delivering on the intent of Olive Carty's Will is clearly their focus when making decisions. They are enquiring and challenging in considering our approach, both of which are positive traits in fellow Trustees, I wish to also thank the dedicated management team of Glen Thomson, and Nick Doherty for their support and advice.

## **The Future**

I look forward to the year ahead as the Trustees and I continue to engage with key leaders in the medical research sector to ensure that we are supporting the bright midcareer researchers who are making significant contributions to this sector in Victoria.

In times of immense strain on the availability of funds to undertake medical research, the LEW Carty Signature grants offer great opportunities to seed innovative research and address a funding gap that cannot be easily filled by other national funding agencies.

We look forward to reviewing the progress of our existing grantees in FY24 as we continue to consider the best approach for the LEW Carty Charitable Trust to have an impact.

**Susan Harker**  
**Chair**

30 November 2023

# *Our Founder*

## Olive Muriel Carty



Olive Muriel Carty

The L.E.W. Carty Charitable Fund is an independent philanthropic foundation established under the will of Olive Carty, who died on 26 February 1977.

Olive's story is not only her legacy, the L.E.W. Carty Charitable Fund, but also her life and the impact she had on others throughout her remarkable 72 years.

Olive Muriel Bishop was born in the residential seaside suburb of Brighton in Melbourne's south-east on 24 March 1904.

Olive was the sixth child of seven for John Bishop and Jemima Gibson MacVean who had married on 24 October 1894 at the Manse, Brunswick in a ceremony conducted by Jemima's father, Reverend Allan MacVean. Reverend MacVean had been lauded for his interest and commitment to charitable work, guidance, and counsel with regards to local institutions. There is no doubt Olive's grandfather's sense of giving and charitability was ingrained in the family values.

In Olive's early years, when her father John was busy at his accounting firm, Jemima would have been running the family home in Brighton where she would have seen her sons off to school at the prestigious Scotch College, Hawthorn, and preparing her daughters for a life where the expectation was to marry and begin a family. It is likely the Bishop girls surpassed the education expectation of the time and experienced a good education in the private school system.

After the heartache of the First World War with the loss of Olive's elder brother Alan, Australia entered the 1920s with great anticipation. In about May of 1928, the Bishop family moved from Brighton, the house they had called home for about 30 years, to the leafy residential suburb of Toorak. In August 1928 while Jemima, her son Rex and three of her daughters, Ellen, Olive, and Ivie settled in at Sherwood 8 Glenbervie Road, Toorak, John and daughters Mary and Kathleen spent eight months travelling through England and Europe.

On 9 December 1929 the Bishop's world was rocked when Jemima died at the age of 64. Interestingly it was Jemima who had purchased Sherwood. Divided equally amongst the six Bishop women – Jemima, Mary, Marjorie, Kathleen, Olive, and Ivie, essentially it offered a form of financial security without the need for a male to oversee their living arrangements.

The Bishop family had cause for celebration in 1931 when Olive's sister Marjorie married John Bell.

Further family celebration ensued as on 21 March 1935, Olive Muriel Bishop walked down the aisle of St John's Church, Toorak on the arm of her father towards her soon-to-be husband, Leslie Ernest William Carty. It is unclear how the two came to meet as there was an age difference of 20 years – Olive was 30 years old to Leslie's 50 years – and a physical distance of more than 300 kilometres between them. The wedding, reported with much fanfare in the local newspapers of the day,

described a radiant Olive, and the groom, Leslie was attended by two groomsmen: Harold Archer – his sister Lucy's husband – and his soon-to-be brother in law Rex Bishop. The inclusion of his future wife's brother in the bridal party speaks to the acceptance of Leslie into the close family fold.

What a shock it must have been for Olive to move from the bustling inner suburbs of Melbourne and central business district where her father's offices were located at 99 Queen Street, to the vast pastoral runs of Hamilton as a wife and mistress of the homestead, with Leslie who had lived his whole life on the family property known as Brisbane Hill. Upon Olive's arrival at Brisbane Hill and the Western District she quickly mucked into work on the farm and involved herself in the community.

From her early years in Hamilton, Olive became a member of the Napier Club. The Napier Club had – and still has to this day – an emphasis on community, volunteering, and charity. It was a place for women to gather in a social setting and to organise and host events for women in the rural area.

Four years after Leslie and Olive married, the unthinkable happened, the world was again plunged into war. For a period the Women's Auxiliary Australian Air Force (W.A.A.A.F.) Officers' Club and Headquarters were housed at the Napier Club.

With the end of the war and the evacuation of the W.A.A.A.F. from the Napier Club, it would have been difficult work to return the club to its former glory, however, that fell to Olive who became the president, and remained a member, in the post-war years. Olive would have been a highly respected and valued member of the community to have been voted as the president of the prestigious women's club in a town in which she had only been a resident for 10 years – a blink of an eye for rural communities. Olive was capable, a strength that would have allowed her to flourish once she moved to Brisbane Hill. She was also not stereotypical of her time and had independent means which implied that she had no need to rely on her husband and was able to make decisions autonomously.

Olive and Leslie continued to live and work at Brisbane Hill and contribute to the Hamilton community. Sadly, on 12 June 1961 at the age of 75 years, Leslie Ernest William Carty died. He had suffered from congestive heart disease for many years. Olive was only 57 years old on the death of Leslie. She remained at Brisbane Hill for a short time before returning to live in Melbourne.

Once Olive returned to Melbourne she lived independently and had stronger connections with Wilson, Bishop & Henderson, the accounting firm her father had been integral in establishing, and where her brother Rex was still presiding. Had Olive had the opportunity for further study beyond what was required for females of her generation, it is feasible to believe she would have progressed into the business world.

Love and care for others is never a certainty in life, however, a big part of Olive's legacy is that the care she showed her extended family was immeasurable.

Olive's vibrancy and vivaciousness was renowned within the family. She was not the shy and retiring type, she loved outrage and had a wonderful sense of humour. She always had an interest in medical matters and became fascinated by the change in societies attitude towards women.

Olive's bequest of \$200,000 was made to Trustees on 20 February 1980 to establish a perpetual charitable fund to assist or promote medical research within Victoria. Olive determined the fund be named the 'L.E.W. Carty Charitable Fund', in memory of her late husband whom she had loved, admired, and respected during their 26 years together.

# Grants

## How We Grant

The L.E.W. Carty Charitable Fund is a perpetual charitable trust and its grants strategy reflects the legal parameters of Olive Carty's will. Within these boundaries, our grants strategy continuously responds to changes and developments in the field of medical research. For further information visit our website [www.carty.org.au](http://www.carty.org.au)

## Our Grantmaking Charter

- To distribute grants in accordance with the terms of the Will of the late Olive Muriel Carty to honour the memory of her late husband Leslie Ernest William Carty. The L.E.W. Carty Charitable Fund makes grants to registered charities within the State of Victoria, being a hospital, institution, society, organisation, body or fund, that are in need of funds to assist or promote research into the diagnosis, prevention or treatment of physical or mental disorders of human beings.
- To select grants to appropriate charities at the absolute discretion of the Board of Trustees.
- To act in all of its dealings as an independent, non-politically aligned entity.

## Our Grantmaking Goals

The opportunity to apply for a L.E.W. Carty Signature Grant of up to \$375,000 over three years is offered to Victorian medical research institutions to support pilot concepts and novel research initiatives. Funding is considered for research projects in a variety of disciplines including, but not limited to, basic science, clinical and public health.

Our Signature Grants aim to nurture mid-career researchers and, where practical, to retain leading researchers in Victoria. One grant per year is awarded

Each grant provides significant funding for a researcher who has already generated some amount of preliminary data, but is required to demonstrate additional, significant progress before the applicant can apply to governmental or other funding agencies.

Ideally, our grant will fund a project in an established laboratory that will serve as the basis for the applicant to grow and build a research team. At present, we are engaging with medical research institutes that we have recently funded and gaining an understanding of their leading mid-career researcher projects for consideration for funding.

# 2023 Carty Signature Grant

## Kiryu Yap - St Vincent's Institute



Dr Kiryu Yap

Dr Kiryu Yap is a clinician-scientist with a PhD in biomedical research, a medical degree, and an MBA. This unique skillset gives Kiryu a competitive advantage in conducting translational research by being able to identify clinically relevant ideas addressing unmet needs and attracting essential collaborators such as clinicians and industry partners. Kiryu is Co-Laboratory Head of Vascular Biology at St Vincent's Institute of Medical Research (SVI).

Kiryu's aim is to progress SVI's liver organoid research from an experimental and pre-clinical stage towards large animal trials, with the view to leading a future clinical trial on campus. He is also keenly interested in the commercial aspects of research and hopes to increase SVI's industry collaborations to progress their work towards commercialisation through partnerships or licensing options.

### **Research project: Treating fatty liver disease using designer human liver organoids**

Liver disease is a silent epidemic. Up to 6 million Australians (25% of the population) have liver disease, with most being asymptomatic until the very late stages when irreversible scarring and failure of liver function can lead to rapid death. In the last 3 decades fatty liver disease has become the most prevalent form of liver disease. Fatty liver disease is also associated with the development of liver cancer, as well as cardiovascular diseases. This is expected to further increase, even in children. Apart from early intervention with weight reduction and lipid lowering drugs, there are currently no definitive treatments.

The research program will develop a new treatment based on patient specific liver organoids, which are mini liver like entities created from pluripotent stem cells that can then be transplanted back into the patient. To circumvent the risk of fatty liver disease recurring in the newly transplanted liver organoids, gene editing will be used to knock out a critical gene *CIDEB* which has shown to be protective against the development of fatty liver disease by preventing the accumulation of lipids in liver cells.

Kiryu will lead this research project as it aims to provide a new and permanent cure for people with fatty liver disease. These individuals currently have no treatment options once their livers are irreversibly damaged, apart from a liver transplant, which even then does not lead to a lasting cure for a substantial portion of patients.

Although many different types of liver diseases have been studied in an experimental setting when applying these new regenerative approaches, it is noteworthy that none have tackled fatty liver disease. This is because even if the diseased liver is replaced via stem cell or organoid therapy, it will become diseased again. However, with the addition of a gene-editing approach to make disease-resistant organoids, Kiryu aims to circumvent this issue. This research combines several cutting-edge strategies which make it different from any other approaches currently being studied.



# Financial Summary

## Statement of surplus or deficit and other comprehensive income for the year ended 30 June 2023

|  |                                     | 2023             | 2022        |
|--|-------------------------------------|------------------|-------------|
|  |                                     | \$               | \$          |
| <b>REVENUE</b>                                 |                                     |                  |             |
|  | Dividends and distributions         | <b>404,099</b>   | 973,008     |
|  | Imputation credits                  | <b>129,424</b>   | 356,639     |
|  | Interest income                     | <b>47,055</b>    | 3,203       |
|  |                                     | <b>580,578</b>   | 1,332,850   |
| <b>EXPENSES</b>                                |                                     |                  |             |
|  | Administrative expenses             | <b>(50,977)</b>  | (47,168)    |
|  | Audit review fees                   | <b>(6,100)</b>   | (5,800)     |
|  | Trustee benefits                    | <b>(12,000)</b>  | (12,000)    |
|  |                                     | <b>(69,077)</b>  | (64,968)    |
| <b>OPERATING SURPLUS</b>                       |                                     | <b>511,501</b>   | 1,267,882   |
|  | Grants approved during year         | <b>(410,000)</b> | (300,000)   |
| <b>SURPLUS FOR THE YEAR</b>                    |                                     | <b>101,501</b>   | 967,882     |
| <b>Other comprehensive income</b>              | Change in fair value of investments | <b>1,229,676</b> | (1,872,741) |
| <b>TOTAL COMPREHENSIVE INCOME FOR THE YEAR</b> |                                     | <b>1,331,177</b> | (904,859)   |
|  | Attributable to Capital Account     | <b>1,254,827</b> | (1,125,885) |
|  | Attributable to Income Account      | <b>76,350</b>    | 221,026     |
|  |                                     | <b>1,331,177</b> | (904,859)   |

## Financial Summary *continued*

### Statement of financial position as at 30 June 2023

|                                |                                 | 2023              | 2022       |
|--------------------------------|---------------------------------|-------------------|------------|
|                                |                                 | \$                | \$         |
| <b>CURRENT ASSETS</b>          | Cash and cash equivalents       | <b>1,596,354</b>  | 1,473,732  |
|                                | Trade and other receivables     | <b>204,302</b>    | 425,292    |
|                                |                                 | <b>1,800,656</b>  | 1,899,024  |
| <b>NON-CURRENT ASSETS</b>      | Investment in financial assets  | <b>11,451,611</b> | 10,136,766 |
|                                |                                 | <b>11,451,611</b> | 10,136,766 |
| <b>TOTAL ASSETS</b>            |                                 | <b>13,252,267</b> | 12,035,790 |
| <b>CURRENT LIABILITIES</b>     | Trade and other payables        | <b>266,100</b>    | 405,800    |
|                                |                                 | <b>266,100</b>    | 405,800    |
| <b>NON-CURRENT LIABILITIES</b> | Trade and other payables        | <b>325,000</b>    | 300,000    |
|                                |                                 | <b>325,000</b>    | 300,000    |
| <b>TOTAL LIABILITIES</b>       |                                 | <b>591,100</b>    | 705,800    |
| <b>NET ASSETS</b>              |                                 | <b>12,661,167</b> | 11,329,990 |
| <b>ACCUMULATED FUNDS</b>       |                                 |                   |            |
| <b>Attributable to:</b>        |                                 |                   |            |
| <b>Capital Account</b>         | Settlement sum                  | <b>200,000</b>    | 200,000    |
|                                | Capital reserve                 | <b>9,101,106</b>  | 8,863,665  |
|                                | Investments revaluation reserve | <b>2,993,418</b>  | 1,911,032  |
|                                |                                 | <b>12,294,524</b> | 10,974,697 |
| <b>Income Account</b>          | Retained surplus                | <b>366,643</b>    | 355,293    |
|                                |                                 | <b>366,643</b>    | 355,293    |
| <b>TOTAL ACCUMULATED FUNDS</b> |                                 | <b>12,661,167</b> | 11,329,990 |